Company news

Rezolute, Inc. (NASDAQ:RZLT) news

Rezolute, Inc. news releases on 6ix. Latest, Oct 5, 2026: Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting…

Rezolute, Inc. (NASDAQ:RZLT) news

Press releases & updates

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism

Rezolute Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting

Rezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual Meeting

Rezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting

Rezolute to Participate in the Citizens Life Sciences Conference

Rezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism

Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Rezolute to Host Virtual Investor Event on Ersodetug Development Program

Rezolute to Participate in Upcoming Investor Conferences

Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update

Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism

Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer

XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)

Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism

Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute, Inc. Announces Closing of Underwritten Offering

Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants

Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)

Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference

Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism

Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update

FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study

Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism

Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants

Rezolute to Participate in the Jefferies Global Healthcare Conference

Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)

Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update